These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11249520)

  • 21. Orlistat: a review of its use in the management of obesity.
    Henness S; Perry CM
    Drugs; 2006; 66(12):1625-56. PubMed ID: 16956313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orlistat in the treatment of obesity.
    Hollander P
    Prim Care; 2003 Jun; 30(2):427-40. PubMed ID: 14567157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orlistat-associated adverse effects and drug interactions: a critical review.
    Filippatos TD; Derdemezis CS; Gazi IF; Nakou ES; Mikhailidis DP; Elisaf MS
    Drug Saf; 2008; 31(1):53-65. PubMed ID: 18095746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review article: malnutrition and maltreatment--a comment on orlistat for the treatment of obesity.
    Cahill A; Lean ME
    Aliment Pharmacol Ther; 1999 Aug; 13(8):997-1002. PubMed ID: 10468673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orlistat. No hurry...
    Can Fam Physician; 1999 Oct; 45():2331-3, 2336-8, 2343-5 passim. PubMed ID: 10540693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.
    Shirai K; Fujita T; Tanaka M; Fujii Y; Shimomasuda M; Sakai S; Samukawa Y
    Adv Ther; 2019 Jan; 36(1):86-100. PubMed ID: 30535651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
    Nelson RH; Miles JM
    Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exercise training as an adjunct to orlistat therapy reduces oxidative stress in obese subjects.
    Ozcelik O; Ozkan Y; Karatas F; Kelestimur H
    Tohoku J Exp Med; 2005 Aug; 206(4):313-8. PubMed ID: 15997202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Orlistat (Xenical)].
    Crenier L; Sternon J
    Rev Med Brux; 1999 Jun; 20(3):159-63. PubMed ID: 10429540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of orlistat in weight management.
    Marks S
    Aust Fam Physician; 2001 Apr; 30(4):335-8. PubMed ID: 11355219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advancements in drug treatment of obesity.
    Carter R; Mouralidarane A; Ray S; Soeda J; Oben J
    Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP; St-Pierre S; Tremblay A
    Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.
    Di Marco M; Marier JF; Ducharme MP; Morin I; Engel C; Gulbranson S; Thudi NR; Murpani D; Rampal A; Monif T; Koundinya TS; Deo K; Monif T
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):319-26. PubMed ID: 18541129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
    Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
    Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.